Press Center
Get an overview of Priothera’s recent news articles, and keep up-to-date with our ongoing work and results.
If you are a professional member of the media and would like to find out more about Priothera, please contact info@priothera.com.
Innover pour mieux soigner – Les cancers du sang avec Priothera
Florent Gros, Cofondateur et Président de Priothera, nous dévoile les ambitions de son entreprise spécialisée dans le traitement des hémopathies malignes, notamment la leucémie myéloïde aiguë (LMA). Entre innovation thérapeutique et défis d’une biotech en pleine croissance, il nous partage sa vision pour transformer les traitements et améliorer la survie des patients atteints de cancers du sang.
Priothera to Present Trial in Progress Poster for Mocravimod at 2024 American Society of Hematology (ASH) Annual Meeting
Mocravimod is being investigated in a global MO-TRANS Phase III study in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation...
EUROAPI and Priothera enter into CDMO collaboration to advance oncology project
EUROAPI and Priothera, a biotechnology company specializing in the trea…
Priothera – US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies
Mocravimod is the only S1P receptor modulator being developed as an…
Priothera cleared to begin Japanese arm of pivotal Phase III study with mocravimod in patients with Acute Myeloid Leukemia undergoing allogeneic Hematopoietic Cell Transplant
Mocravimod is the only S1PR modulator being developed as an adjunctive and…
Priothera announces first patients enrolled in pivotal MO-TRANS global Phase IIb/III study with mocravimod as an adjunctive and maintenance therapy for patients with Acute Myeloid Leukemia (AML) undergoing allogeneic Hematopoietic Cell Transplant (HCT)
Mocravimod is the only S1PR modulator being developed to treat blood cancers…